ESE-1 is a Novel Transcriptional Mediator of Angiopoietin-1 Expression in the Setting of Inflammation
Courtney Brown,John Gaspar,Allison Pettit,Rebecca Lee,Xuesong Gu,Hong Wang,Cathy Manning,Carole Voland,Steven R. Goldring,Mary B. Goldring,Towia A. Libermann,Ellen M. Gravallese,Peter Oettgen
DOI: https://doi.org/10.1074/jbc.m308593200
IF: 5.485
2004-01-01
Journal of Biological Chemistry
Abstract:Angiogenesis is a critical component of the inflammatory response associated with a number of conditions. Angiopoietin-1 (Ang-1) is an angiogenic growth factor that promotes the chemotaxis of endothelial cells and facilitates the maturation of new blood vessels. Ang-1 expression is up-regulated in response to tumor necrosis factor-α (TNF-α). To begin to elucidate the underlying molecular mechanisms by which Ang-1 gene expression is regulated during inflammation, we isolated 3.2 kb of the Ang-1 promoter that contain regulatory elements sufficient to mediate induction of the promoter in response to TNF-α, interleukin-1β, and endotoxin. Surprisingly, sequence analysis of this promoter failed to reveal binding sites for transcription factors that are frequently associated with mediating inflammatory responses, such as NF-κB, STAT, NFAT, or C/EBP. However, putative binding sites for ETS and AP-1 transcription factor family members were identified. Interestingly, among a panel of ETS factors tested in a transient transfection assay, only the ETS factor ESE-1 was capable of transactivating the Ang-1 promoter. ESE-1 binds to specific ETS sites within the Ang-1 promoter that are functionally important for transactivation by ESE-1. ESE-1 and Ang-1 are induced in synovial fibroblasts in response to inflammatory cytokines, with ESE-1 induction slightly preceding that of Ang-1. Mutation of a high-affinity ESE-1 binding site leads to a marked reduction in Ang-1 transactivation by ESE-1, inducibility by inflammatory cytokines, and DNA binding to the ESE-1 protein. Transcriptional profiling of cells transiently transfected with an ESE-1 expression vector demonstrates that the endogenous Ang-1 gene is directly inducible by ESE-1. Finally, Ang-1 and ESE-1 exhibit a similar and strong expression pattern in the synovium of patients with rheumatoid arthritis. Our results support a novel paradigm for the ETS factor ESE-1 as a transcriptional mediator of angiogenesis in the setting of inflammation. Angiogenesis is a critical component of the inflammatory response associated with a number of conditions. Angiopoietin-1 (Ang-1) is an angiogenic growth factor that promotes the chemotaxis of endothelial cells and facilitates the maturation of new blood vessels. Ang-1 expression is up-regulated in response to tumor necrosis factor-α (TNF-α). To begin to elucidate the underlying molecular mechanisms by which Ang-1 gene expression is regulated during inflammation, we isolated 3.2 kb of the Ang-1 promoter that contain regulatory elements sufficient to mediate induction of the promoter in response to TNF-α, interleukin-1β, and endotoxin. Surprisingly, sequence analysis of this promoter failed to reveal binding sites for transcription factors that are frequently associated with mediating inflammatory responses, such as NF-κB, STAT, NFAT, or C/EBP. However, putative binding sites for ETS and AP-1 transcription factor family members were identified. Interestingly, among a panel of ETS factors tested in a transient transfection assay, only the ETS factor ESE-1 was capable of transactivating the Ang-1 promoter. ESE-1 binds to specific ETS sites within the Ang-1 promoter that are functionally important for transactivation by ESE-1. ESE-1 and Ang-1 are induced in synovial fibroblasts in response to inflammatory cytokines, with ESE-1 induction slightly preceding that of Ang-1. Mutation of a high-affinity ESE-1 binding site leads to a marked reduction in Ang-1 transactivation by ESE-1, inducibility by inflammatory cytokines, and DNA binding to the ESE-1 protein. Transcriptional profiling of cells transiently transfected with an ESE-1 expression vector demonstrates that the endogenous Ang-1 gene is directly inducible by ESE-1. Finally, Ang-1 and ESE-1 exhibit a similar and strong expression pattern in the synovium of patients with rheumatoid arthritis. Our results support a novel paradigm for the ETS factor ESE-1 as a transcriptional mediator of angiogenesis in the setting of inflammation. Inflammation is an important component of several pathological conditions, including wound healing, atherosclerosis, and arthritis. Inflammation is often associated with the development of granulation tissue consisting of infiltrating mononuclear cells and blood vessels (1Jackson J.R. Seed M.P. Kircher C.H. Willoughby D.A. Winkler J.D. Faseb J. 1997; 11: 457-465Crossref PubMed Scopus (611) Google Scholar, 2Koch A.E. Harlow L.A. Haines G.K. Amento E.P. Unemori E.N. Wong W.L. Pope R.M. Ferrara N. J. Immunol. 1994; 152: 4149-4156PubMed Google Scholar). As this tissue proliferates there are zones of relative hypoxia where growth of the tissue has outstripped the blood vessel supply, triggering signals for further blood vessel development (3Walsh D.A. Rheumatology (Oxford). 1999; 38: 103-112Crossref PubMed Scopus (210) Google Scholar). The angiogenesis that results from these signals provides the necessary blood supply, oxygen, and nutrients to support the proliferating tissue, and plays an active role in the transport of inflammatory cells to the site of inflammation (4Koch A.E. Arthritis Rheum. 1998; 41: 951-962Crossref PubMed Scopus (434) Google Scholar). The endothelial cells themselves also provide a source of proinflammatory cytokines.One of the first steps in this process is the induction of angiogenic growth factors such as basic fibroblast growth factor (bFGF) 1The abbreviations used are: bFGF, basic fibroblast growth factor; FCS, fetal calf serum; DMEM, Dulbecco's modified Eagle's medium; VEGF, vascular endothelial growth factor; Ang-1, angiopoietin-1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RA, rheumatoid arthritis; TNF, tumor necrosis factor; RT, reverse transcriptase; TBS, Tris-buffered saline. 1The abbreviations used are: bFGF, basic fibroblast growth factor; FCS, fetal calf serum; DMEM, Dulbecco's modified Eagle's medium; VEGF, vascular endothelial growth factor; Ang-1, angiopoietin-1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RA, rheumatoid arthritis; TNF, tumor necrosis factor; RT, reverse transcriptase; TBS, Tris-buffered saline. and vascular endothelial growth factor (VEGF) (5Senger D.R. Claffey K.P. Benes J.E. Perruzzi C.A. Sergiou A.P. Detmar M. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 13612-13617Crossref PubMed Scopus (454) Google Scholar). These growth factors promote the proliferation and migration of endothelial cells to sites of inflammation, which is facilitated by the expression of matrix degrading enzymes and integrins on activated endothelial cells (6Senger D.R. Ledbetter S.R. Claffey K.P. Papadopoulos-Sergiou A. Peruzzi C.A. Detmar M. Am. J. Pathol. 1996; 149: 293-305PubMed Google Scholar). Endothelial cells that have migrated to sites of inflammation then organize into small tubes. The formation of stable blood vessels requires the recruitment of surrounding mesenchymal cells and their differentiation into vascular smooth muscle cells. Vessel maturation is facilitated by the angiopoietins (7Suri C. Jones P.F. Patan S. Bartunkova S. Maisonpierre P.C. Davis S. Sato T.N. Yancopoulos G.D. Cell. 1996; 87: 1171-1180Abstract Full Text Full Text PDF PubMed Scopus (2371) Google Scholar).Ang-1 has the unique property of enhancing the stability of new blood vessels by recruiting surrounding mesenchymal cells and promoting their differentiation to vascular smooth muscle cells (7Suri C. Jones P.F. Patan S. Bartunkova S. Maisonpierre P.C. Davis S. Sato T.N. Yancopoulos G.D. Cell. 1996; 87: 1171-1180Abstract Full Text Full Text PDF PubMed Scopus (2371) Google Scholar). In contrast to other angiogenic substances like VEGF or bFGF, Ang-1 is not a potent mitogen for endothelial growth. However, Ang-1 is a potent chemoattractant of endothelial cells and enhances endothelial cell migration. Other properties of Ang-1 include its ability to promote the adhesion of endothelial cells to fibronectin, as well as its ability to prevent endothelial cell death by inhibiting apoptosis (8Huang X.L. Takakura N. Suda T. Biochem. Biophys. Res. Commun. 1999; 264: 133-138Crossref PubMed Scopus (29) Google Scholar, 9Fujikawa K. de Aos Scherpenseel I. Jain S.K. Presman E. Varticovski L. Exp. Cell Res. 1999; 253: 663-672Crossref PubMed Scopus (125) Google Scholar).We and others (10Gravallese E.M. Pettit A.R. Lee R. Madore R. Manning C. Tsay A. Gaspar J. Goldring M.B. Goldring S.R. Oettgen P. Ann. Rheum. Dis. 2003; 62: 100-107Crossref PubMed Scopus (80) Google Scholar, 11Scott B.B. Zaratin P.F. Colombo A. Hansbury M.J. Winkler J.D. Jackson J.R. J. Rheumatol. 2002; 29: 230-239PubMed Google Scholar, 12Shahrara S. Volin M.V. Connors M.A. Haines G.K. Koch A.E. Arthritis Res. 2002; 4: 201-208Crossref PubMed Scopus (101) Google Scholar) have recently demonstrated that Ang-1 mRNA and protein are expressed in the synovium of patients with rheumatoid arthritis (RA). Ang-1 is expressed at low levels in primary human synovial fibroblasts obtained from patients with RA, and can be markedly up-regulated in response to inflammatory cytokines such as TNF-α. However, the transcriptional mechanisms by which Ang-1 gene expression is regulated are currently unknown.The purpose of this study was to begin to identify the molecular mechanisms of Ang-1 gene regulation in the setting of inflammation. Our findings support a central role for the ETS transcription factor ESE-1 during this process. ESE-1 was originally identified as a transcription factor that, under basal conditions, is highly restricted to cells of epithelial origin (13Oettgen P. Alani R.M. Barcinski M.A. Brown L. Akbarali Y. Boltax J. Kunsch C. Munger K. Libermann T.A. Mol. Cell. Biol. 1997; 17: 4419-4433Crossref PubMed Scopus (198) Google Scholar). However, in response to inflammatory stimuli, this factor can be induced in a variety of non-epithelial cells, including vascular smooth muscle cells, chondrocytes, synovial fibroblasts, and endothelial cells (14Rudders S. Gaspar J. Madore R. Voland C. Grall F. Patel A. Pellacani A. Perrella M.A. Libermann T.A. Oettgen P. J. Biol. Chem. 2001; 276: 3302-3309Abstract Full Text Full Text PDF PubMed Scopus (81) Google Scholar, 15Grall F. Gu X. Tan L. Cho J.Y. Inan M.S. Pettit A.R. Thamrongsak U. Choy B.K. Manning C. Akbarali Y. Zerbini L. Rudders S. Goldring S.R. Gravallese E.M. Oettgen P. Goldring M.B. Libermann T.A. Arthritis Rheum. 2003; 48: 1249-1260Crossref PubMed Scopus (88) Google Scholar). We recently demonstrated that ESE-1 is highly expressed in the synovium of patients with rheumatoid arthritis (15Grall F. Gu X. Tan L. Cho J.Y. Inan M.S. Pettit A.R. Thamrongsak U. Choy B.K. Manning C. Akbarali Y. Zerbini L. Rudders S. Goldring S.R. Gravallese E.M. Oettgen P. Goldring M.B. Libermann T.A. Arthritis Rheum. 2003; 48: 1249-1260Crossref PubMed Scopus (88) Google Scholar). In this study we present direct evidence indicating a role for ESE-1 in Ang-1 gene regulation. ESE-1 can bind to specific ETS sites within the Ang-1 promoter that are functionally important for the transactivation by ESE-1, expression of ESE-1 in cultured cells leads to induction of the endogenous Ang-1 gene, and Ang-1 exhibits a similar and strong expression pattern in the synovium of patients with RA. In summary, our results support a role for the ETS factor ESE-1 as a novel transcriptional regulator of Ang-1 gene regulation in the setting of inflammation.EXPERIMENTAL PROCEDURESTissue Culture and Reagents—The cell lines HEK293 (human embryonic kidney), NIH3T3 (mouse fibroblast), and MCF-7 (human breast cancer) were grown in DMEM supplemented with 10% fetal calf serum (FCS; Hyclone, Logan, UT) and antibiotics (penicillin and streptomycin; Invitrogen). Synovial tissue and bone were obtained at the time of arthroplasty or joint replacement surgery from patients with the clinical diagnosis of RA. Tissue procurement was approved by the Institutional Review Board. Dispersed synovial tissues were prepared by a previously published method (16Gravallese E.M. Manning C. Tsay A. Naito A. Pan C. Amento E. Goldring S.R. Arthritis Rheum. 2000; 43: 250-258Crossref PubMed Scopus (615) Google Scholar). Briefly, synovial tissues were minced on tissue culture plates and treated with Type I collagenase (4 mg/ml; Worthington Biochemical Corporation, Lakewood, NJ), in DMEM (Invitrogen), incubated for 1 h at 37 °C, treated with 0.25% trypsin for 30 min, harvested, and centrifuged at 1,000 rpm for 10 min. Pellets were suspended in 0.05% trypsin-0.02% EDTA, centrifuged, and resuspended in 50% phosphate-buffered saline (Ca2+/Mg2+-free), 50% DMEM containing 10% FCS (Sigma). Cells were then centrifuged and suspended in DMEM, 10% FCS, and plated at a density of 10 × 106 cells/10-cm plate. Cells were initially grown for 7–10 days and subsequently subjected to 2–4 passages. TNF-α and interleukin-1β (IL-1β) were purchased from R&D Systems (Minneapolis, MN).Expression Vector and Luciferase Reporter Gene Constructs—3239-, 1998-, and 1020-bp fragments corresponding to nucleotides -3040 to +199, -1799 to +199, and -821 to +199 of the human Ang-1 promoter were cloned from human genomic DNA (Clontech, Palo Alto, CA) by PCR and subcloned into the pGL2 luciferase reporter vector (Promega, Madison, WI). The 1998- and 1020-bp fragments were inserted into the XhoI-HindIII site and the 3239-bp fragment was inserted into the HindIII site upstream of the luciferase gene of the pGL2 vector.DNA Transfection Assays—Cotransfections of 2 × 105 HEK293 or NIH3T3 cells were carried out with varying amounts of reporter gene construct DNA and expression vector DNA using 4 μl of LipofectAMINE (Invitrogen) as described (17Oettgen P. Akbarali Y. Boltax J. Best J. Kunsch C. Libermann T.A. Mol. Cell. Biol. 1996; 16: 5091-5106Crossref PubMed Scopus (72) Google Scholar). The cells were harvested 16 h after transfection and assayed for luciferase activity. Transfections for every construct were performed independently in duplicates. Cotransfection of a second plasmid for determination of transfection efficiency was omitted because potential artifacts with this technique have been reported and because many commonly used viral promoters contain potential binding sites for ETS factors (18Farr A. Roman A. Nucleic Acids Res. 1992; 20: 920Crossref PubMed Scopus (115) Google Scholar).Site-directed Mutagenesis—Site-directed mutagenesis of the Ang-1 promoter was performed using the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's recommendations. In brief, PCR primers encoding the Ang-1 promoter ETS site, -1565 to -1562, and flanking sequences were used, with ATAT substituted for ATCC: 5′-TGTGAATTACATATTGTTAGCCTT-3′ and 3′-AAGGCTAACAATATGTAATTCACA-5′. PCR was performed with Turbo polymerase using the wild type Ang-1 promoter fragment C luciferase reporter construct as a template. The PCR reaction was digested with DpnI, and the undigested plasmids were transformed into DH5α bacteria. Individual minipreps were sequenced to verify incorporation of the ETS site mutation.Electrophoretic Mobility Shift Assay—These were performed as described previously (19Dube A. Akbarali Y. Sato T.N. Libermann T.A. Oettgen P. Circ. Res. 1999; 84: 1177-1185Crossref PubMed Scopus (92) Google Scholar). In brief, whole cell extracts were made from primary human synovial fibroblasts after incubation with TNF-α or IL-1β for 0, 2, 6, 18, 24, and 48 h, using as lysis buffer 10% glycerol, 0.5% Nonidet P-40, 150 mm NaCl, 10 mm Tris pH 7.4, 1 mm phenylmethanesulfonyl fluoride, and 1 mm dithiothreitol. Whole cell extracts were obtained instead of nuclear extracts because the number of cells were limited and the primary synovial fibroblasts do not maintain their phenotype after 4–5 passages. 10 μg of whole cell extract or 2 μl of in vitro translation product and 0.1–0.2 ng of [32P]dATP-labeled double-stranded oligonucleotide probes (5,000–20,000 cpm) in the presence or absence of antibody were run on 4% polyacrylamide gels containing 0.5× TBE buffer. For supershift assays, 1 μl of rabbit polyclonal anti-ESE-1 antibody raised against a glutathione S-transferase fusion protein of the N terminus of human ESE-1 (East Acres Biologicals, Southbridge, MA) was used.Oligonucleotides used as probes are as follows (ETS consensus binding sites underlined: 1) human Ang-1 promoter site -2586 to -2567, 5′-TTTAATGCATCCTGAATTCT-3′ and 3′-AGAATTCAGGATGCATTAAA-5′; 2) human Ang-1 promoter site -2207 to -2188, 5′-TTCCCTCAGGAAATTGTGCA-3′ and 3′-TGCACAATTTCCTGAGGGAA-5′; 3) human Ang-1 promoter site -1573 to -1554, 5′-TGAATTACATCCTGTTAGCC-3′ and 3′-GGCTAACAGGATGTAATTCA-5′; 4) human Ang-1 promoter mutated site -1573 to -1554, 5′-GCTCTGTTGAATTACATATTGTTAGCCTTTC-3′ and 3′-GAAAGGCTAACAATATGTAATTCACAGAGC-5′.RT-PCR—Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA). cDNAs were generated from 2 μg of mRNA isolated from human synovial fibroblasts using oligo(dT)12–18 priming (Invitrogen) and Moloney murine leukemia virus-reverse transcriptase (Invitrogen). ESE-1, AML-1, and GAPDH RT-PCRs used equivalent amounts of 0.1 ng of cDNA, 4 ng/μl of each primer, 0.25 units of Taq polymerase (Promega), 150 μm of each dNTP, 3 mm of MgCl2, reaction buffer, and water to a final volume of 25 μl. Ang-1 RT-PCRs used equivalent amounts of 0.1 ng of cDNA, 4 ng/μl of each primer, 0.25 units of Advantage cDNA polymerase mix (Clontech), 150 μm of each dNTP, reaction buffer, and water to a final volume of 25 μl.The sequences of the primers used in this study are as follows: 1) Human ESE-1: sense, 5′-ACCTGGATCCCACTGATGGCAAGCTC-3′ and antisense, 5′-GGAGGAAGAGGTTCTCCAGAGTCGG-3′, with an expected amplification product of 457 bp. 2) Human Ang-1: sense, 5′-TTTCCTCGCTGCCATTCTGACTC-3′, and antisense, 5′-TATGGATGTCAATGGGGGAGGTT-3′, with an expected amplification product of 947bp. 3) Human AML-1: sense, 5′-AAGTCGCCACCTACCACAG-3′ and antisense, 5′-CTCAGCCTCAGAGTCAGATGC-3′, with an expected amplification product of 248 bp (21Niini T. Vettenranta K. Hollmen J. Larramendy M.L. Aalto Y. Wikman H. Nagy B. Seppanen J.K. Ferrer Salvador A. Mannila H. Saarinen-Pihkala U.M. Knuutila S. Leukemia. 2002; 16: 2213-2221Crossref PubMed Scopus (30) Google Scholar). 4) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH): sense, 5′-CAAAGTTGTCATGGATGACC-3′ and antisense, 5′-CCATGGAGAAGGCTGGGG-3′, with an expected amplification product of 200 bp.RT-PCR amplifications were carried out using a MJ Research thermal cycler PTC-100 as follows: ESE-1, 32 cycles of 30 s at 94 °C and 1 min 30 s at 68 °C followed by 7 min at 68 °C; Ang-1, 35 cycles of 30 s at 94 °C, and 1 min 30 s at 64 °C followed by 7 min at 64 °C; AML-1, 32 cycles of 30 s at 94 °C, 1 min at 60 °C, and 1 min 30 s at 72 °C followed by 10 min at 72 °C; GAPDH, 32 cycles of 30 s at 94 °C, 1 min at 56 °C, and 1 min 30 s at 72 °C followed by 10 min at 72 °C. 5 μl of the amplification product was analyzed on a 2% agarose gel.Western Blot Analysis—Whole cell lysates (50 μg) of MCF7 cells were boiled in Laemmli buffer and resolved on 10% SDS-PAGE acrylamide gel. Proteins were transferred on Hybond-polyvinylidene difluoride membranes and immunoblotted using the ECL Western blotting Detection reagents (Amersham Biosciences). Rabbit polyclonal anti-ESE-1 antibody raised against a glutathione S-transferase fusion protein of the N terminus of human ESE-1 (East Acres Biologicals, Southbridge, MA) was used at a dilution of 1:1,000, and revealed with an anti-rabbit horseradish peroxydase antibody (Cell Signaling Technology, Beverly, MA) at a dilution of 1:1,000.cDNA Microarrays—Microarray experiments were performed as previously described (22Gu X. Shin B.H. Akbarali Y. Weiss A. Boltax J. Oettgen P. Libermann T.A. J. Biol. Chem. 2001; 276: 9421-9436Abstract Full Text Full Text PDF PubMed Scopus (41) Google Scholar). In brief, 1 × 106 human breast cancer MCF-7 cells were transiently transfected in duplicates with 8 μg of PCI-ESE-1 or PCI plasmid using the LipofectAMINE Plus system (Invitrogen). Total RNA was isolated separately from each plate 24 h after transfection using the RNeasy Kit (Qiagen) according to the manufacturer's instructions. Atlas Human Cancer 1.2 cDNA microarray nylon membranes (Clontech), each containing 1176 different genes, were hybridized with [32P]dATP-labeled cDNAs derived from 4 μg of total RNA according to the manufacturer at 68 °C in ExpressHyb solution (Clontech) using a Model 2000 Micro Hybridization Incubator (Robbins Scientific, Sunnyvale, CA). The filters were washed according to the user's instruction and exposed to Bio-Max MS film (Fisher) for different exposure times. Hybridizations were performed with duplicate experiments. The spot intensities reflecting gene expression levels on the Atlas human cDNA array were quantified using the Atlas Image 2.0 Software (Clontech). The transcriptional profiles in the cells overexpressing ESE-1 were compared with those in the cells transfected with parental PCI vector, normalizing spot intensities based on the average of the intensities of all spots. Genes up-regulated or down-regulated by ESE-1 were validated by RT-PCR.Immunohistochemistry—RA synovial soft tissue and bone were fixed for 48 h in 4% paraformaldehyde and specimens containing bone were subsequently decalcified for at least 2 weeks in 14% EDTA. Specimens were processed for paraffin embedding (Citadel 1000; Shandon, Pittsburgh, PA) and 4- or 5-μm serial sections were cut for immunohistochemical staining using an immunoperoxidase technique with diaminobenzidine (DAB; Dako, Carpinteria, CA) as the chromogen. Briefly, sections were deparaffinized followed by microwave antigen retrieval (GE Sensor convection microwave oven) in 10 mm EDTA pH 7.5 at 93 °C for 10 min and allowed to cool for at least 2 h. Sections were washed in Tris-buffered saline (TBS) and incubated for 60 min in serum block (10% fetal bovine serum and 10% normal rabbit serum diluted in TBS). Sections were then incubated with an affinity purified rabbit polyclonal anti-human Ang-1 antibody (L41309M, Regeneron Pharmaceuticals Inc., Tarrytown, NY), purified rabbit polyclonal anti-human ESE-1 antibody (AB3482, Chemicon International, Temecula, CA), or with an isotype matched control antibody (polyclonal Rabbit IgG, Santa Cruz Biotechnology Inc, Santa Cruz, CA) for 60 min. All incubations were carried out at room temperature. Sections were washed between every subsequent step with TBS. Endogenous peroxidase activity was blocked by incubating the sections in 3% H2O2 (diluted in TBS) for 30 min. Sections were subsequently incubated for 30 min with a biotinylated F(ab′)2 fragment of swine anti-rabbit immunoglobulin (Dako), followed by horseradish peroxidase-conjugated streptavidin (Dako), and developed with DAB (Dako) chromogen to the manufacturer's specifications. The sections were counterstained with hematoxylin (Sigma Diagnostics). Slides were examined and photographed using a transmitted light microscope and camera (Zeiss, Oberkochen, Germany).RESULTSIsolation and Characterization of the Human Ang-1 Promoter— The molecular mechanisms required for the induction of Ang-1 in response to inflammatory cytokines are currently unknown. To begin to identify potential mechanisms of Ang-1 gene regulation we isolated a series of genomic fragments (Fig. 1, A–C) of the human Ang-1 promoter, up to 3.2 kb in length, by long range PCR using human genomic DNA. The entire sequence of the Ang-1 gene is published in the human genome data base (accession NT 008046). Verification of the sequence was performed by automated sequencing. Comparison of the mouse and human Ang-1 promoter sequences revealed a relatively high overall degree of sequence homology. We examined the human Ang-1 promoter sequence for potential binding sites for transcription factors known to be involved in inflammation, such as NF-κB, JAK/STAT, PPAR, NFAT, and C/EBP. Surprisingly, no obvious binding site for any of these transcription factor families was identified. However, putative binding sites for members of the AP-1 and ETS families were identified. In addition, putative AML-1 and CBF-β binding sites were identified in the Ang-1 promoter.Induction of the Ang-1 Promoter by Inflammatory Cytokines—To evaluate whether the Ang-1 promoter contains regulatory elements capable of mediating induction in response to inflammatory cytokines the three genomic fragments encoding the Ang-1 promoter (A–C) were incorporated into the pGL2 luciferase reporter construct. NIH3T3 fibroblasts were transiently transfected with each Ang-1 reporter construct, followed by stimulation with TNF-α (Fig. 2A). We have previously demonstrated that TNF-α consistently induces Ang-1 mRNA expression in cultured synovial fibroblasts (10Gravallese E.M. Pettit A.R. Lee R. Madore R. Manning C. Tsay A. Gaspar J. Goldring M.B. Goldring S.R. Oettgen P. Ann. Rheum. Dis. 2003; 62: 100-107Crossref PubMed Scopus (80) Google Scholar). Stimulation of the 3.2-kb Ang-1 promoter construct C (-3040/+199) with TNF-α resulted in a 4-fold induction of the promoter. Similarly, stimulation of the 2-kb construct B (-1799/+199) with TNF-α led to a 4-fold increase in transactivation. However, further deletion to a 1-kb construct (Ang-1 A, -821/+199) markedly reduced the inducibility of the promoter to TNF-α, suggesting that the main regulatory elements responsible for mediating induction of the Ang-1 gene reside in the nucleotide region between -1799 and -821. We also examined the inducibility of constructs A and B in NIH3T3 fibroblasts after stimulation with IL-1β and LPS (Fig. 2, B and C). A 4–5-fold level of induction of the activity of construct B was seen in response to IL-1β and LPS, but no induction was seen with construct A, suggesting the importance of regulatory elements between nucleotides -1799 and -821 in mediating this induction of Ang-1 gene expression. This region contains putative AP-1 and ETS binding sites (Fig. 1).Fig. 2Transactivation of the Ang-1 promoter in response to inflammatory stimuli. Transactivation studies of Ang-1 luciferase reporter constructs A (-821/+199), B (-1799/+199), and C (-3040/+199) (300 ng each) in NIH3T3 fibroblasts after stimulation with TNF-α (50 ng/ml) (A), IL-1β (1 ng/ml) (B), or LPS (1 ng/ml) (C). The change in luciferase activity of the promoter construct after stimulation is expressed as fold induction compared with the activity of the promoter construct in unstimulated cells (DMEM supplemented with 10% FCS).View Large Image Figure ViewerDownload Hi-res image Download (PPT)Transactivation of the Ang-1 Promoter by ETS Factors—As shown in Fig. 1, there are several putative binding sites for members of the ETS transcription factor family in the Ang-1 promoter. Selected members of the ETS transcription factor family have been shown previously to mediate the induction of other genes associated with inflammatory responses (23Wasylyk B. Hahn S.L. Giovane A. Eur. J. Biochem. 1993; 211: 7-18Crossref PubMed Scopus (809) Google Scholar, 24Kramer B. Wiegmann K. Kronke M. J. Biol. Chem. 1995; 270: 6577-6583Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). We therefore postulated that ETS factors might also be involved in the regulation of Ang-1 in response to inflammatory stimuli and tested the ability of a panel of ETS factors to transactivate the full-length Ang-1 promoter. Cotransfection experiments using mammalian expression plasmids encoding a panel of ETS factors and the 3.2-kb Ang-1 promoter luciferase construct were performed in HEK293 cells. We chose HEK293 cells because they do not express Ang-1 and can be transfected with high efficiency. As is shown in Fig. 3, only one of the ETS factors tested, ESE-1, was able to transactivate the Ang-1 promoter by ∼3-fold. These results suggest that ESE-1 is a potential transcriptional regulator of the Ang-1 promoter.Fig. 3Transactivation of the Ang-1 promoter by a panel of ETS factors. Transactivation of the 3.2-kb Ang-1 luciferase reporter construct C (-3040/+199) (300 ng) by a panel of ETS transcription factors (150 ng each) compared with the empty mammalian expression plasmid (PCI, 150 ng) in HEK293 cells. The change in luciferase activity is expressed as fold induction compared with PCI.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Binding of ESE-1 to Putative ETS Binding Sites—To further define the potential role of ESE-1 in the regulation of Ang-1, we evaluated the ability of ESE-1 to bind to putative ETS binding sites identified in the Ang-1 promoter by performing gel mobility shift assays. Three putative ETS binding sites were identified in the Ang-1 promoter corresponding to regions beginning at -2578, -2199, and -1565 (Fig. 1). The binding of in vitro translated ESE-1 protein was compared with control extracts in a gel mobility shift assay using radiolabeled oligonucleotides encoding the three putative ETS binding sites (Fig. 4). Whereas weak binding of ESE-1 to the first two sites (lanes 2 and 4) compared with the control extract (lanes 1 and 3) was observed, ESE-1 bound with high affinity to the third site (lane 6). Interestingly, this high affinity ESE-1 binding site (-1565/-1562) is located within the region of the Ang-1 promoter that is required for induction by inflammatory cytokines, whereas the low affinity sites are not.Fig. 4Gel mobility shift assays for ESE-1 binding to putative ETS sites in the Ang-1 promoter. In vitro translated ESE-1 protein (lanes 2, 4, 6) or control extract (lanes 1, 3, 5) was used with end-labeled oligonucleotide probes encoding putative ETS sites starting at positions -2578 (lanes 1 and 2), -2199 (lanes 3 and 4), and -1565